概括
高风险特征显著影响了激素受体阳性,HER2阳性乳腺癌患者的内拉替尼布处方. 剩余疾病没有影响决策,这表明生物风险指南辅助使用涅拉替尼.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 涅拉提尼布是一种对HER2阳性乳腺癌有效的铁氨酸激酶抑制剂.
- 在ExteNET试验显示,内拉替尼提高了HR+ HER2+乳腺癌的生存率后trastuzumab.
- 目前尼拉替尼的使用早于珀图祖马布和T-DM1,需要在当代实践中进行评估.
研究的目的:
- 评估影响当前实践中内拉替尼布处方的临床特征.
- 评估高风险疾病特征在内拉替尼布处方决策中的作用.
- 为了确定残留疾病是否会影响涅拉替尼的处方.
主要方法:
- 对HR+ HER2+乳腺癌患者的回顾性评估符合接受涅拉替尼的条件 (2017-2024年).
- 从电子病历中提取临床和治疗数据.
- 使用已确定的标准和关于Ki-67和瘤等级的文献来定义高风险状态.
主要成果:
- 确定了107名符合条件的患者;67人提供了涅拉替尼,40人没有.
- 在接受涅拉替尼治疗的患者中,高风险疾病的患病率显著增加 (p<0.01).
- 两组之间残留疾病或进展率没有显著差异.
结论:
- 高风险的临床特征强烈影响了neratinib的处方.
- 疾病残留状况似乎不会影响涅拉替尼的处方决定.
- 生物风险标准可以为辅助性内拉提尼布的使用提供实际指导.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.0K
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
418
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
